Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.70 +6.1%	$7.99	$6.10 ▼ $28.67	$602.51M	1.6	394,268 shs	249,129 shs
CMPS COMPASS Pathways	$4.14 -1.9%	$3.54	$2.49 ▼ $8.54	$384.39M	2.27	850,201 shs	1.03 million shs
TBPH Theravance Biopharma	$9.30 +1.6%	$9.16	$7.44 ▼ $10.90	$465.01M	-0.1	268,874 shs	127,572 shs
TRDA Entrada Therapeutics	$7.90 +1.7%	$8.41	$7.10 ▼ $21.79	$299.83M	0.04	130,942 shs	87,408 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	+2.12%	+1.86%	-2.38%	-25.66%	-64.32%
CMPS COMPASS Pathways	-1.40%	-2.76%	+8.76%	+7.65%	-43.28%
TBPH Theravance Biopharma	-1.40%	-2.76%	-6.15%	-1.29%	+8.80%
TRDA Entrada Therapeutics	+0.91%	+1.04%	-12.40%	-35.14%	-51.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.2279 of 5 stars	4.4	1.0	1.9	4.2	0.6
CMPS COMPASS Pathways	1.9792 of 5 stars	3.5	1.0	3.2	0.8	0.6
TBPH Theravance Biopharma	1.0472 of 5 stars	2.1	0.0	2.7	2.5	0.6
TRDA Entrada Therapeutics	2.7947 of 5 stars	3.6	2.0	2.8	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	187.36% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	354.91% Upside
TBPH Theravance Biopharma	2.25	Hold	$11.33	21.86% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	224.89% Upside

Current Analyst Ratings Breakdown

Latest BCYC, TBPH, TRDA, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00
4/9/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$25.72M	23.42	N/A	N/A	$12.35 per share	0.70
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
TBPH Theravance Biopharma	$65.27M	7.12	N/A	N/A	$4.28 per share	2.17
TRDA Entrada Therapeutics	$172.22M	1.74	N/A	N/A	$7.26 per share	1.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$180.66M	-$3.14	N/A	N/A	N/A	-450.64%	-27.35%	-20.81%	8/5/2025 (Estimated)
CMPS COMPASS Pathways	-$118.46M	-$1.99	N/A	N/A	N/A	N/A	-63.85%	-51.97%	8/7/2025 (Estimated)
TBPH Theravance Biopharma	-$55.19M	-$1.18	N/A	26.57	N/A	-78.18%	-24.79%	-13.43%	8/4/2025 (Estimated)
TRDA Entrada Therapeutics	-$6.68M	$0.81	4.97	N/A	N/A	25.53%	16.11%	10.39%	8/12/2025 (Estimated)

Latest BCYC, TBPH, TRDA, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	17.13	17.13
CMPS COMPASS Pathways	0.15	8.91	8.91
TBPH Theravance Biopharma	N/A	4.97	4.97
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
CMPS COMPASS Pathways	46.19%
TBPH Theravance Biopharma	99.10%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
CMPS COMPASS Pathways	4.25%
TBPH Theravance Biopharma	6.90%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.18 million	Optionable
CMPS COMPASS Pathways	120	92.85 million	65.51 million	Optionable
TBPH Theravance Biopharma	359	50.00 million	45.78 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable

BCYC, TBPH, TRDA, and CMPS Headlines

Recent News About These Companies

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28 at 7:00 AM | globenewswire.com

Q2 EPS Estimate for Entrada Therapeutics Raised by Analyst

May 24, 2025 | marketbeat.com

HC Wainwright Has Positive Forecast for TRDA Q2 Earnings

May 24, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for TRDA Q2 Earnings?

May 23, 2025 | marketbeat.com

Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 23, 2025 | marketbeat.com

Q2 Earnings Forecast for TRDA Issued By HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics' (TRDA) "Buy" Rating Reaffirmed at HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC Wainwright

May 22, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 17, 2025 | marketbeat.com

MPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 16, 2025 | marketbeat.com

Q2 EPS Forecast for Entrada Therapeutics Reduced by Analyst

May 16, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP

May 16, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results

May 12, 2025 | marketbeat.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MD

May 2, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

May 1, 2025 | marketbeat.com

Entrada Cuts 20% of Workforce, Targeting Research Employees

April 30, 2025 | biospace.com

Entrada lays off 20% of staff weeks after having FDA hold lifted

April 30, 2025 | fiercebiotech.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, TBPH, TRDA, and CMPS Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.70 +0.50 (+6.10%)

Closing price 04:00 PM Eastern

Extended Trading

$8.70 +0.00 (+0.05%)

As of 04:29 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

COMPASS Pathways NASDAQ:CMPS

$4.14 -0.08 (-1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$4.17 +0.03 (+0.72%)

As of 07:28 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Theravance Biopharma NASDAQ:TBPH

$9.30 +0.15 (+1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$9.30 -0.01 (-0.05%)

As of 04:04 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Entrada Therapeutics NASDAQ:TRDA

$7.90 +0.13 (+1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$7.90 +0.00 (+0.06%)

As of 04:04 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time